Estudo randomizado fase 2 | FOLFOXIRI (ácido folínico, 5-fluorouracila, oxaliplatina e irinotecano) antecipada com bevacizumabe com ou sem atezolizumabe no tratamento de pacientes com câncer colorretal metastático.
16 Jun, 2022 | 11:58hUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
In phase II AtezoTRIBE study of the addition of atezolizumab to first-line FOLFOXIRI + bevacizumab improved PFS in pts with pMMR/MSS mCRC (median 13.1 vs 11.5 months; adjusted HR 0.70, 80% CI 0.57–0.87; P = 0.018): https://t.co/0dkRxjvjsx #ImmunoOnc #CRCSM
— NatureRevClinOncol (@NatRevClinOncol) May 31, 2022